Gainers
- Sundial Growers SNDL stock increased by 28.49% to $0.93 during Friday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q3 earnings report came out yesterday.
- Eledon Pharmaceuticals ELDN shares rose 11.11% to $5.5. The market value of their outstanding shares is at $78.6 million. The company's, Q3 earnings came out yesterday.
- Pluristem Therapeutics PSTI stock rose 10.64% to $3.22. The market value of their outstanding shares is at $103.3 million. As per the news, the Q1 earnings report came out 4 days ago.
- Homology Medicines FIXX stock moved upwards by 9.02% to $6.4. The market value of their outstanding shares is at $365.3 million.
- Biofrontera BFRI shares moved upwards by 9.01% to $3.75. The market value of their outstanding shares is at $43.5 million.
- SOC Telemed TLMD shares moved upwards by 8.45% to $2.31. The company's market cap stands at $231.2 million. As per the news, the Q3 earnings report came out today.
Losers
- Catalyst Biosciences CBIO stock declined by 30.96% to $2.03 during Friday's pre-market session. The company's market cap stands at $63.6 million.
- Aditxt ADTX stock decreased by 13.82% to $1.56. The company's market cap stands at $41.9 million.
- Beyond Air XAIR shares decreased by 8.55% to $10.06. The company's market cap stands at $240.9 million. As per the press release, Q2 earnings came out yesterday.
- Iterum Therapeutics ITRM stock fell 7.87% to $0.56. The market value of their outstanding shares is at $102.5 million. As per the press release, Q3 earnings came out today.
- Repro-Med Systems KRMD shares decreased by 6.8% to $3.29. The company's market cap stands at $146.4 million. As per the news, the Q3 earnings report came out 2 days ago.
- Avinger AVGR shares declined by 6.49% to $0.72. The company's market cap stands at $68.8 million. As per the press release, Q3 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in